复宏汉霖:地舒单抗注射液在欧盟获批上市 覆盖原研所有适应症

证券日报
Sep 22

  本报讯 (记者金婉霞)9月19日,上海复宏汉霖生物技术股份有限公司(以下简称“复宏汉霖”)的微信公众号显示,公司60mg/mL和120mg/1.7mL两规格的地舒单抗注射液已获得欧盟委员会(EC)的上市许可,适应症覆盖了原研产品在欧盟已获批的所有适应症。

  复宏汉霖首席商务发展官兼高级副总裁曹平表示,此次获批是复宏汉霖与合作伙伴强强联合、共同满足欧洲患者和医疗系统需求的又一重要成果。“凭借对科学卓越与产品质量的始终坚守,我们在美国获批的基础上不断前行,将这些生物类似药治疗方案带给全球更多有需要的患者。”曹平称。

(文章来源:证券日报)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10